H Olschewski, G Simonneau, N Galie, T … - New England Journal of Medicine, 2002 - content.nejm.org Methods We compared repeated daily inhalations of 2.5 or 5.0 µg of iloprost
(six or nine times per day; median inhaled dose, 30 µg per day) with inhalation
of placebo. A total of 203 patients with selected forms of severe pulmonary ... Cited by 846 - Related articles - BL Direct - All 19 versions
- ►171.66.122.149 G Simonneau, RJ Barst, N Galie, R Naeije, S … - American journal of respiratory and critical care …, 2002 - 171.66.122.149 Pulmonary arterial hypertension is a life-threatening disease for which
continuous intravenous prostacyclin has proven to be effective. However, this
treatment requires a permanent central venous catheter with the associated ... Cited by 628 - Related articles - BL Direct - All 9 versions
- ►utmem.edu [PDF] MM Hoeper, M Schwarze, S Ehlerding, A … - New England Journal of Medicine, 2000 - content.nejm.org Results Twenty-four patients with primary pulmonary hypertension received
aerosolized iloprost at a daily dose of 100 or 150 µg for at least one year.
The mean (±SD) distance covered in the six-minute walk test increased from ... Cited by 457 - Related articles - BL Direct - All 11 versions
HA Ghofrani, R Wiedemann, F Rose, RT … - The Lancet, 2002 - Elsevier Pulmonary vascular resistance index was reduced by nitric oxide (−21·9%, 95%
Cl −14·1 to −36·2), epoprostenol (−36·9%, −24·4 to −59·6), and
sildenafil (−32·5%, −10·2 to −54·1). However, ratio of pulmonary ... Cited by 437 - Related articles - All 7 versions
- ►annals.org [PDF] HA Ghofrani, R Wiedemann, F Rose, H … - Annals of internal medicine, 2002 - Am Coll Physicians Patients: 30 patients with severe pulmonary arterial hypertension (n 16),
chronic thromboembolic pulmonary hypertension (n 13), or pulmonary hypertension
due to aplasia of the left pulmo- nary artery (n 1), all classified as New ... Cited by 424 - Related articles - BL Direct - All 14 versions
- ►ahajournals.org H Wilkens, A Guth, J Konig, N Forestier, B … - Circulation, 2001 - Am Heart Assoc Methods and Results— The short-term effects of 8.4 to 10.5 µg of aerosolized
iloprost, the phosphodiesterase type 5 inhibitor sildenafil, and the combination
thereof were compared in 5 patients with primary pulmonary hypertension. ... Cited by 365 - Related articles - BL Direct - All 11 versions
- ►onlinejacc.org RJ Barst, M McGoon, V McLaughlin, V Tapson, … - Journal of the American College of Cardiology, 2003 - Elsevier A total of 116 patients with World Health Organization (WHO) functional class II
or III primary pulmonary hypertension or PAH related to either collagen vascular
diseases or congenital systemic to pulmonary shunts were enrolled. Patients ... Cited by 306 - Related articles - BL Direct - All 5 versions
- ►westhertshospitals.nhs.uk [PDF] JR Runo, JE Loyd - The Lancet, 2003 - Elsevier Primary pulmonary hypertension (PPH) is a rare disorder characterised by raised
pulmonary-artery pressure in the absence of secondary causes. Precapillary
pulmonary arteries are affected by medial hypertrophy, intimal fibrosis, ... Cited by 301 - Related articles - All 13 versions
- ►onlinejacc.org HA Ghofrani, F Rose, RT Schermuly, H … - Journal of the American College of Cardiology, 2003 - Elsevier We sought to investigate the impact of adjunct sildenafil on exercise capacity
and hemodynamic parameters in patients with pulmonary arterial hypertension
(PAH) who fulfilled predefined criteria of deterioration despite ongoing ... Cited by 265 - Related articles - BL Direct - All 15 versions
- ►atsjournals.org VV McLaughlin, RJ Oudiz, A Frost, VF Tapson … - American journal of respiratory and critical care …, 2006 - Am Thoracic Soc Measurements and Main Results: A total of 67 patients with PAH (55% idiopathic
PAH, 45% associated PAH, 94% NYHA class III, and mean baseline 6-MWD of 335 m)
were randomized. At Week 12, patients receiving iloprost had a mean ... Cited by 160 - Related articles - BL Direct - All 6 versions
